Skip to content

Role of Prucalopride treatment of chronic constipation in Parkinson disease

Role of Prucalopride treatment of chronic constipation in Parkinson disease

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200211001
Enrollment
80
Registered
2020-02-11
Start date
2020-02-19
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who were diagnosed as Parkinson&#39

Interventions

Prucalopride 2 mg/day,A placebo pill in an identicle fashion
Experimental Drug,Placebo Comparator No treatment

Sponsors

Faculty of Medicine, Siriraj Hospital
Lead Sponsor
Faculty of Medicine&#44
Collaborator
Siriraj Hospital
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria - patients who age of >/=18 years old - Has been diagnosed as Parkinson disease according to UKPDS Brain bank criteria who are in stable disease (no need for medication adjustment at least 4 weeks before enrollment. - Met criteria of chronic constipation according to ROME IV criteria (ROME IV diagnosis criteria for constipation)

Exclusion criteria

Exclusion criteria: Exclusion Criteria - Had alternative cause of chronic constipation eg. o History of abdominal surgery except anorectal surgery, appendectomy and cholecystectomy. o Recieve drugs which effect GI motility eg. opioids, anticholinergic agents o Have endrocrinologic disease or metabolic derangement which caused constipation eg.hypothyroidism, hypercalcemia o megacolon/megarectum, pseudo-colonic obstruction - Has been diagnosed as colonic cancer before the enrolment all participants with age 50 year should be underwent colonic cancer screening - Allergic to prucalopride or medication component. - Currently treated with prucalopride before the enrollment. - Severe dementia or unable to fill the questionnaires. - Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
efficacy of medication week 2, 4 and 8 frequency of bowel movement

Secondary

MeasureTime frame
constipation related quality of life week 2, 4 and 8 questionnaire

Countries

Thailand

Contacts

Public ContactMonthira Maneerattanaporn

Faculty of Medicine Siriraj Hospital, Mahidol University

monthira.man@mahidol.ac.th0816979551

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026